LeMaitre Vascular Inc (NASDAQ: LMAT) has reported E.P.S. of $0.38 for its fourth fiscal quarter (ending December 31) versus $0.26 for the same period a year ago — an increase of 46%. This performance was $0.03 better than the consensus estimate of $0.35. E.P.S. were $1.36 for the latest four quarters through December 31 versus $0.94 for the same period a year ago — an increase of 45%.
Recent Price Action
On 2/27/24, LeMaitre Vascular Inc (NASDAQ: LMAT) stock rose modestly by 0.7%, closing at $62.11. Moreover, unusually high trading volume at 164% of normal accompanied the advance. The stock has been weak relative to the market over the last nine months and has declined -0.7% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, LMAT is expected to be a Value Builder.
LeMaitre Vascular has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects complementary signals from PTR’s two proprietary measures of a stock’s attractiveness. LeMaitre Vascular has a slightly negative Power Rating of 35 and a very low Appreciation Score of 13, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment